Pathogenese des atopischen Ekzems

Scheerer, Cora; Eyerich, Kilian

doi:10.1007/s00105-018-4127-4

Cited by 19 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Paeonol is an active component extracted from the TCM Cortex Moutan, which is widely used and has high clinical development prospects (20,21). Numerous pharmacological and clinical studies have confirmed the biological properties of paeonol, including anti-inflammatory, anti-bacterial and antitumor effects (22,23). Our previous study demonstrated that oral administration of paeonol results in anti-inflammatory and immunoregulatory effects in BALB/c mice with psoriasis-like lesions (16).…”

Section: Discussionmentioning

confidence: 99%

Paeonol inhibits the development of 1‑chloro‑2,4‑dinitrobenzene‑induced atopic dermatitis via mast and T cells in BALB/c mice

et al. 2019

View full text Add to dashboard Cite

Our previous studies suggested that paeonol, the active constituent of the traditional Chinese medicine Cortex Moutan, may be an effective treatment for inflammatory disorders. In the present study, the therapeutic potential of paeonol on atopic dermatitis (AD) was investigated using animal and cell experiments. AD-like lesions were induced by repeated application of 1-chloro-2,4-dinitrobenzene (DNCB) to the shaved dorsal skin of BALB/c mice, and P815 cells were used for in vitro assays. The skin lesions, serum and spleens of the mice were analyzed using lesion severity scoring, histological analysis, flow cytometry, reverse transcription-quantitative polymerase chain reaction, western blotting and ELISA, in order to investigate the anti-AD effects of paeonol. In addition, western blotting and ELISA were conducted for in vitro analysis of P815 cells. The results demonstrated that oral administration of paeonol inhibited the development of DNCB-induced AD-like lesions in the BALB/c mice by reducing severity of the lesions, epidermal thickness and mast cell infiltration; this was accompanied by reduced levels of immunoglobulin E and inflammatory cytokines [interleukin (IL)-4, histamine, IL-13, IL-31 and thymic stromal lymphopoietin], along with regulation of the T helper (Th) cell subset (Th1/Th2) ratio. Application of paeonol also reduced the protein expression levels of phosphorylated (p)-p38 and p-extracellular signal-regulated kinase (ERK) in skin lesions. In vitro, paeonol reduced the expression levels of tumor necrosis factor-α and histamine in P815 cells, and inhibited p38/ERK/mitogen-activated protein kinase signaling. The present findings indicated that paeonol may relieve dermatitis by acting on cluster of differentiation 4+ T and mast cells; therefore, paeonol may represent a potential therapeutic strategy for the treatment of allergic inflammatory conditions via immunoregulation.

show abstract

Section: Discussionmentioning

confidence: 99%

Paeonol inhibits the development of 1‑chloro‑2,4‑dinitrobenzene‑induced atopic dermatitis via mast and T cells in BALB/c mice

et al. 2019

View full text Add to dashboard Cite

show abstract

“…[51][52][53][54][55][56][57][58][59] Finally, there is hope for new effective treatments for the severely affected patients with atopic eczema in the future. [51][52][53][54][55][56][57][58][59] Finally, there is hope for new effective treatments for the severely affected patients with atopic eczema in the future.…”

Section: Discussionmentioning

confidence: 99%

“…There is a silver streak of hope on the horizon with the appearance of new targeted therapies with biologics such as monoclonal antibodies against relevant cytokines or receptors, for example the interleukin 4 receptor (dupilumab), interleukin 5 (mepolizumab), interleukin 13 (tralokinumab), interleukin 31 (nemolizumab) as well as new kinase inhibitors and others. [51][52][53][54][55][56][57][58][59] Finally, there is hope for new effective treatments for the severely affected patients with atopic eczema in the future.…”

Section: Discussionmentioning

confidence: 99%

Atopic eczema: burden of disease and individual suffering – results from a large EU study in adults

Ring

Zink

Arents

et al. 2019

Acad Dermatol Venereol

119

112

View full text Add to dashboard Cite

Background Atopic eczema (AE, atopic dermatitis) is one of the most common non‐communicable inflammatory skin diseases affecting 1–5% of the adult population in Europe with marked impairment in quality of life. In spite of great progress in understanding the pathophysiology of disturbed skin barrier and immune deviation, AE still represents a problem in daily clinical practice. Furthermore, the true impact of AE on individual suffering is often not recognized. Objectives With a large European study, we wanted to provide insights into the actual suffering and individual burden of disease in adult patients with AE. Methods A total of 1189 adult patients (18–87 years, 56% female) with moderate to severe AE were recruited in nine European countries by dermatologists or allergists together with the help of patient organizations. A computer‐assisted telephone interview was performed by experienced interviewers between October 2017 and March 2018. The following instruments were used to assess severity or measure quality of life: Patient‐Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), Hospital Anxiety and Depression Scale (HADS‐D) and a newly developed Atopic Eczema Score of Emotional Consequences (AESEC). Patients were also asked to self‐assess the severity of their disease. Results Despite current treatment, 45% of participants still had actual moderate to very severe AE in POEM. Due to their skin disease, 57% missed at least 1 day of work in the preceding year. DLQI showed moderate to extremely large impairment in 55%. According to HADS‐D, 10% scored on or above the threshold of eight points with signs of depressive symptoms. Assessed with AESEC, 57% were emotionally burdened with feelings such as ‘trying to hide the eczema’, ‘feeling guilty about eczema’, having ‘problems with intimacy’ and more. Of persons actually suffering from severe AE, 88% stated that their AE at least partly compromised their ability to face life. Conclusions This real‐life study shows that adults with a moderate to severe form of AE are suffering more than what would be deemed acceptable. There is a need for increased awareness of this problem among healthcare professionals, policymakers and the general public to support research in the development of new and more effective treatments and provide access to better and affordable health care for affected patients.

show abstract

“…The chronic or relapsing nature of AE, with itch as the predominant symptom, can have a huge impact on affected individuals (4). Several studies have shown that physical wellbeing and quality of life can be severely impaired, especially in patients with severe AE (5)(6)(7)(8). However, to date, the impact and intensity of symptoms in the daily life of individuals with AE have gained limited attention.…”

mentioning

confidence: 99%

Out-of-pocket Costs for Individuals with Atopic Eczema: A Cross-sectional Study in Nine European Countries

Zink¹,

Arents²,

Fink-Wagner³

et al. 2019

Acta Derm Venerol

101

View full text Add to dashboard Cite

SIGNIFICANCEAtopic eczema is a skin disease with a huge impact on the everyday lives of affected patients' and their families, but little awareness in the general population. This study including 1,189 people with atopic eczema living in 9 Euro pean countries found that extra out-of-pocket spending due to the atopic eczema is another setback with a mean amount of €927 spent by every patient per year. Out-of-pocket costs are a substantial burden in atopic eczema and much higher than in other chronic diseases. These costs should always be taken into account in individual as well as economic assessments of the disease.Atopic eczema is one of the most common non-communicable inflammatory skin diseases, and has a huge socioeconomic impact. Studies on the everyday economic impact of atopic eczema on patients, however, are limited. To estimate the annual extra out-of-pocket spending due to atopic eczema among patients in Europe, a cross-sectional study using computer-assisted phone interviewing of patients with atopic eczema was performed in 9 European countries. A total of 1,189 patients (56% women) with atopic eczema, who were either eligible for, or on, systemic treatment, participated in the study between October 2017 and March 2018. Mean extra spending on everyday necessities was €927 per patient per year for healthcare expenses, and this figure was slightly, but not statistically significantly, influenced by the severity of atopic eczema. Emollients and moisturizers accounted for the highest monthly costs, followed by medication that was not reimbursed, doctors' and hospital costs. Atopic eczema-related out-of-pocket costs pose a substantial burden for affected individuals, are higher than in other chronic diseases, and should always be included in economic assessments of the impact of this disease.

show abstract

Pathogenese des atopischen Ekzems

Cited by 19 publications

References 31 publications

Paeonol inhibits the development of 1‑chloro‑2,4‑dinitrobenzene‑induced atopic dermatitis via mast and T cells in BALB/c mice

Paeonol inhibits the development of 1‑chloro‑2,4‑dinitrobenzene‑induced atopic dermatitis via mast and T cells in BALB/c mice

Atopic eczema: burden of disease and individual suffering – results from a large EU study in adults

Out-of-pocket Costs for Individuals with Atopic Eczema: A Cross-sectional Study in Nine European Countries

Contact Info

Product

Resources

About